Guerbet: Financial agenda for 2024

Financial agenda for 2024

Villepinte, 15 January 2024: Guerbet (FR0000032526), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2024.

Publications calendar

• 2023 ANNUAL REVENUE

February 08, 2024, after trading

• 2023 ANNUAL RESULTS

March 20, 2024, after trading

• 2024 1^ST QUARTER REVENUE

April 25, 2024, after trading

• ANNUAL SHAREHOLDERS' MEETING

May 24, 2024

• 2024 2^ND QUARTER REVENUE

July 25, 2024, after trading

• 2024 FIRST HALF RESULTS

September 25, 2024, after trading

• 2024 3^RD QUARTER REVENUE

October 24, 2024, after trading

About Guerbet

At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 95 years, with more than 2,600 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in four centres in France, Israel, and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B?-?mid caps) and generated €753 million in revenue in 2022.

Contacts :

Guerbet
Jérôme Estampes, Chief Financial Officer + 33.1.45.91.50.00 / [e-mail]
Claire Lauvernier, Group Communication Director +33.6.79.52.11.88 / [e-mail]

Actifin
Marianne Py, Financial Communication + 33.1.80.48.25.31 / [e-mail]
Jennifer Jullia, Media Relations +33.1.56.88.11.19 / [e-mail]